Israel - anglès - Ministry of Health

j-c health care ltd - haloperidol - tablets - haloperidol 5 mg - haloperidol - haloperidol - haldol is indicatedin adult patients aged 18 years and above for:• treatment of schizophrenia and schizoaffective disorder.• acute treatment of delirium when non-pharmacological treatments have failed.• treatment of moderate to severe manic episodes associated with bipolar i disorder when other treatments cannot be used.• treatment of acute psychomotor agitation associated with psychotic disorder or manic episodes of bipolar i disorder.• treatment of persistent aggression and psychotic symptoms in patients with moderate to severe alzheimer’s dementia and vascular dementia when non-pharmacological treatments have failed and when there is a risk of harm to self or others.• treatment of tic disorders, including tourette’s syndrome, in patients with severe impairment after educational, psychological and other pharmacological treatments have failed.• treatment of mild to moderate chorea in huntington’s disease, when other medicinal products are ineffective or not tolerated.in paediatric patients for:• schizophrenia in adolescents aged 13 to 17 years when other pharmacological treatments have failed or are not tolerated.• persistent, severe aggression in children and adolescents aged 6 to 17 years with autism or pervasive developmental disorders, when other treatments have failed or are not tolerated. • tic disorders, including tourette’s syndrome, in children and adolescents aged 10 to 17 years with severe impairment after educational, psychological and other pharmacological treatments have failed.

Israel - anglès - Ministry of Health

j-c health care ltd - haloperidol - solution (oral) - haloperidol 2 mg/ml - haloperidol - haloperidol - haldol is indicatedin adult patients aged 18 years and above for:• treatment of schizophrenia and schizoaffective disorder.• acute treatment of delirium when non-pharmacological treatments have failed.• treatment of moderate to severe manic episodes associated with bipolar i disorder when other treatments cannot be used.• treatment of acute psychomotor agitation associated with psychotic disorder or manic episodes of bipolar i disorder.• treatment of persistent aggression and psychotic symptoms in patients with moderate to severe alzheimer’s dementia and vascular dementia when non-pharmacological treatments have failed and when there is a risk of harm to self or others.• treatment of tic disorders, including tourette’s syndrome, in patients with severe impairment after educational, psychological and other pharmacological treatments have failed.• treatment of mild to moderate chorea in huntington’s disease, when other medicinal products are ineffective or not tolerated.in paediatric patients for:• schizophrenia in adolescents aged 13 to 17 years when other pharmacological treatments have failed or are not tolerated.• persistent, severe aggression in children and adolescents aged 6 to 17 years with autism or pervasive developmental disorders, when other treatments have failed or are not tolerated. • tic disorders, including tourette’s syndrome, in children and adolescents aged 10 to 17 years with severe impairment after educational, psychological and other pharmacological treatments have failed.

Israel - anglès - Ministry of Health

j-c health care ltd - haloperidol as decanoate - solution for injection - haloperidol as decanoate 100 mg/ml - haloperidol - haloperidol - indicated for the maintenance treatment of schizophrenia and schizoaffective disorder in adult patients currently stabilized with oral haloperidol.

Israel - anglès - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ziprasidone as hydrochloride monohydrate - capsules - ziprasidone as hydrochloride monohydrate 40 mg - ziprasidone - ziprasidone - •schizophrenia.treatment of schizophrenia and for maintenance of clinical improvement during continuationtherapy in adults.•bipolar mania.ziprasidone is indicated as monotherapy in the treatment of adults with manic or mixed episodes associatedwith bipolar disorder with or without psychotic features.•bipolar disorder.maintenance treatment of bipolar disorder, as an adjunct to lithium or valproate in adults.

Israel - anglès - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ziprasidone as hydrochloride monohydrate - capsules - ziprasidone as hydrochloride monohydrate 60 mg - ziprasidone - ziprasidone - •schizophrenia.treatment of schizophrenia and for maintenance of clinical improvement during continuationtherapy in adults.•bipolar mania.ziprasidone is indicated as monotherapy in the treatment of adults with manic or mixed episodes associatedwith bipolar disorder with or without psychotic features.•bipolar disorder.maintenance treatment of bipolar disorder, as an adjunct to lithium or valproate in adults.

Israel - anglès - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ziprasidone as hydrochloride monohydrate - capsules - ziprasidone as hydrochloride monohydrate 80 mg - ziprasidone - ziprasidone - •schizophrenia.treatment of schizophrenia and for maintenance of clinical improvement during continuationtherapy in adults.•bipolar mania.ziprasidone is indicated as monotherapy in the treatment of adults with manic or mixed episodes associatedwith bipolar disorder with or without psychotic features.•bipolar disorder.maintenance treatment of bipolar disorder, as an adjunct to lithium or valproate in adults.

Israel - anglès - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ziprasidone as hydrochloride monohydrate - capsules - ziprasidone as hydrochloride monohydrate 20 mg - ziprasidone - ziprasidone - •schizophrenia.treatment of schizophrenia and for maintenance of clinical improvement during continuationtherapy in adults.•bipolar mania.ziprasidone is indicated as monotherapy in the treatment of adults with manic or mixed episodes associatedwith bipolar disorder with or without psychotic features.•bipolar disorder.maintenance treatment of bipolar disorder, as an adjunct to lithium or valproate in adults.

Israel - anglès - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ziprasidone mesylate trihydrate - powder for solution for injection - ziprasidone mesylate trihydrate 40.93 mg - ziprasidone - ziprasidone - rapid control of agitation in patients with schizophrenia, when oral therapy is not appropriate, for a maximum of 3 consecutive days.

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

rowex ltd - domperidone - tablet - 10 milligram(s) - propulsives; domperidone

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

rowex ltd - domperidone - tablet - 10 milligram(s) - propulsives; domperidone